195 related articles for article (PubMed ID: 22035385)
41. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
42. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Saadeh CE; Lee HS
Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
[TBL] [Abstract][Full Text] [Related]
43. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
44. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
[TBL] [Abstract][Full Text] [Related]
45. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
Cohenuram M; Saif MW
Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
[TBL] [Abstract][Full Text] [Related]
46. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab-induced acne.
Molinari E; De Quatrebarbes J; André T; Aractingi S
Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
[TBL] [Abstract][Full Text] [Related]
48. Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy.
Eames T; Kroth J; Flaig MJ; Ruzicka T; Wollenberg A
Acta Derm Venereol; 2010 Mar; 90(2):202-3. PubMed ID: 20169314
[No Abstract] [Full Text] [Related]
49. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
[TBL] [Abstract][Full Text] [Related]
50. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
51. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
52. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
Cohen PR; Escudier SM; Kurzrock R
Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
[TBL] [Abstract][Full Text] [Related]
53. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
54. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
Cignola S; Gonella S; Alessandra B; Palese A
Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
[TBL] [Abstract][Full Text] [Related]
55. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
[TBL] [Abstract][Full Text] [Related]
56. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
58. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
59. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
60. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
Lau SC; Chung V; Lim D; Shibata S
J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]